Ribavirin - Roche

Drug Profile

Ribavirin - Roche

Alternative Names: Copegus; Pegasys RBV; R964

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Antivirals; Furans; Ribonucleosides; Small molecules; Triazoles
  • Mechanism of Action Nucleic acid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 26 Mar 2015 The Japanese MHLW approves ribavirin (Copegus®) in combination with sofosbuvir for use in genotype 2 Hepatitis C patients with compensated cirrhosis related to Hepatitis C (Combination therapy) in Japan
  • 04 Feb 2013 Launched for Hepatitis C (Combination therapy) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top